Jane Street’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-15,600
| Closed | -$281K | – | 8369 |
|
|
2020
Q2 | $281K | Sell |
15,600
-27,500
| -64% | -$383K | ﹤0.01% | 5933 |
|
|
2020
Q1 | $307K | Buy |
43,100
+34,000
| +374% | +$424K | ﹤0.01% | 4178 |
|
|
2019
Q4 | $217K | Buy |
+9,100
| New | +$251K | ﹤0.01% | 4648 |
|
|
2018
Q3 | – | Sell |
-7,600
| Closed | -$287K | – | 5990 |
|
|
2018
Q2 | $287K | Sell |
7,600
-35,900
| -83% | -$1.37M | ﹤0.01% | 4170 |
|
|
2018
Q1 | $1.42M | Buy |
43,500
+37,300
| +602% | +$1.64M | ﹤0.01% | 2242 |
|
|
2017
Q4 | $302K | Buy |
6,200
+1,300
| +27% | +$65.8K | ﹤0.01% | 3768 |
|
|
2017
Q3 | $265K | Sell |
4,900
-85,600
| -95% | -$5.03M | ﹤0.01% | 3832 |
|
|
2017
Q2 | $5.08M | Buy |
+90,500
| New | +$3.62M | 0.02% | 765 |
|
|
2017
Q1 | – | Sell |
-10,400
| Closed | -$233K | – | 4900 |
|
|
2016
Q4 | $233K | Buy |
+10,400
| New | +$203K | ﹤0.01% | 3602 |
|
|
2016
Q2 | – | Sell |
-62,300
| Closed | -$1.27M | – | 4808 |
|
|
2016
Q1 | $1.27M | Buy |
+62,300
| New | +$1.98M | 0.01% | 1632 |
|
Jane Street's PTLA Position: Q2 2020 in Review
Jane Street sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 96,746 shares — an estimated $1.35M sold.
Jane Street first reported a position in PTLA in Q2 2013 and held it in 20 quarters. The position peaked at $2.61M in Q2 2017. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.
- Jane Street reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
- Jane Street sold 96,746 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $1.35M.
- Jane Street first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 20 quarters.
- Jane Street's Portola Pharmaceuticals, Inc. position peaked at $2.61M in Q2 2017.
- 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.
Based on Jane Street's 13F filing for Q2 2020, filed 17 Aug 2020.